CDH18 Mouse Monoclonal Antibody
- Known as:
- CDH18 Mouse Monoclonal Antibody
- Catalog number:
- BIN-001016-M01
- Product Quantity:
- 0.1mg
- Category:
- -
- Supplier:
- Zyagen
- Gene target:
- CDH18 Mouse Monoclonal Antibody
Related genes to: CDH18 Mouse Monoclonal Antibody
- Gene:
- CDH18 NIH gene
- Name:
- cadherin 18
- Previous symbol:
- -
- Synonyms:
- CDH14, EY-CADHERIN
- Chromosome:
- 5p14.3
- Locus Type:
- gene with protein product
- Date approved:
- 1997-06-25
- Date modifiied:
- 2016-01-15
Related products to: CDH18 Mouse Monoclonal Antibody
Related articles to: CDH18 Mouse Monoclonal Antibody
- Well-differentiated (WD) and dedifferentiated (DD) liposarcomas (LPS) are characterized by cyclin-dependent kinase (CDK)4 and mouse double minute 2 homolog (MDM2) amplification. Palbociclib, a selective CDK4/6 inhibitor, demonstrated promising activity in prior phase II trials and is included in the National Comprehensive Cancer Network Compendium for LPS. However, long-term overall survival (OS) data remain limited. - Source: PubMed
Publication date: 2026/03/20
Babatunde O OSeier KSchwartz GKeohan M LD'Angelo S PGounder M MChi PAntonescu C RLanda JQin L-XCrago A MSinger SKoff ATap W DDickson M A - Tenosynovial giant cell tumor (TGCT) is a locally aggressive neoplasm associated with limited range of motion (ROM), stiffness, joint damage, pain, and reduced physical functioning (PF). The MOTION Phase 3 trial (NCT05059262) was a randomized, placebo-controlled, double-blind study of vimseltinib among patients with TGCT. The objective of the current study was to define meaningful changes in clinical outcome assessments (COAs) measuring active ROM, PF, and stiffness using qualitative and quantitative data from patients in the MOTION trial. - Source: PubMed
Publication date: 2026/02/01
Gelhorn Heather LCutts Katelyn NHarrow BrookeTait ChristopherSaunders AmandaFikre TsionHan YipinZeringo Nicholas AVan De Sande MichielTap WilliamGelderblom HansBernthal Nicholas - Uveal melanoma (UM), the most common primary intraocular malignancy in adults, shows racial disparities in incidence, genetic drivers, and clinical outcomes. While most prognostication models are based on Caucasian populations, Asians demonstrate distinct molecular profiles, necessitating population-specific risk stratification. - Source: PubMed
Publication date: 2025/12/02
Luo JingtingChen YuningFeng ZhaoxunLi HaowenXiu JingyingTao YangxuYang QiongLiu YuemingLi YangWei Wenbin - The CDK4/6 inhibitor palbociclib delays progression in patients with advanced dedifferentiated liposarcoma (DDLPS). In carcinoma models, CDK4/6 and PD-1 inhibition induce intratumoral inflammation and synergistic activity. Comprehensive assessment of tumor and host dynamics is needed to understand response and resistance to this combination. - Source: PubMed
Rosenbaum EvanGularte-Mérida RodrigoSeffar EvanLee JasmeAdamow MathewBradic MartinaDickson Mark AAvutu ViswatejBanks Lauren BChan Jason EChi PingGounder Mrinal MKelly Ciara MKeohan Mary LouiseMaki Robert GMovva SujanaReed Damon RDesir RhoenaBiniakewitz MatthewErinjeri Joseph PLefkowitz Robert AWong PhillipAntonescu Cristina RQin Li-XuanPanageas Katherine SShen RonglaiSinger SamuelKoff AndrewTap William DD'Angelo Sandra P - Cardiotoxicity is a concern for patients with sarcoma receiving anthracyclines. Dexrazoxane reduces this risk; however, the timing of administration varies in practice. This study evaluated the association between dexrazoxane timing and anthracycline cardiotoxicity risk. - Source: PubMed
Jang Kristine HWallins Joseph SLin I-HsinMovva SujanaTap William DLiu Jennifer EYu Anthony F